Matinas Bio shares are crushed on disappointing PhII antifungal data
Shares of Matinas BioPharma $MTNB were shredded early Monday after the biotech announced that its lead anti-infectives program failed to match a mainstay in the field in a mid-stage study.
MAT2203 hit the primary endpoint on safety and tolerability, but the biotech’s execs say they were disappointed that the therapy failed to perform as well as fluconazole in treating vulvovaginal candidiasis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.